404 ‒ Mental health beyond neurotransmitters: hormones in psychiatry, psychedelic therapies, & more

Episode Overview

• Dr. Peter Attia interviews Dr. Linus Abrams, a Harvard-trained psychiatrist and psychopharmacologist with nearly 35 years of clinical experience who is also certified as an Advanced Practitioner of Bioidentical Hormone Replacement Therapy (BHRT), to explore how integrating endocrinology with traditional psychiatry moves treatment beyond mere symptom reduction toward the full restoration of human vitality.
• The conversation examines the mechanisms, applications, and limitations of traditional psychotropics—including SSRIs, SNRIs, mood stabilizers, and atypical antipsychotics—while explaining why distinguishing unipolar depression from bipolar spectrum disorders is critical for safe prescribing.
• Moving beyond neurotransmitters, the speakers analyze how modern environmental mismatches, digital isolation, sleep disruption, and chronic pain narrow the human "distress tolerance window" and drive rising rates of depression.
• The core narrative reveals how sex hormones (estradiol, progesterone, and testosterone) and thyroid hormones act as foundational "system modulators" in the brain, culminating in an assessment of HPA-axis stress signaling, ketamine, and classic psychedelics.

Key Concepts

• Symptom Reduction vs. Full Vitality in Psychiatry: Traditional psychiatry aims to reduce symptoms rather than restore the full human experience, and currently lacks objective blood-based or imaging biomarkers (though Abrams notes they do not have them "not yet"). Because symptom relief does not equal vitality, patients often view successful psychopharmacology ambivalently and struggle to stay on regimens. (Abrams hedges that if he asked nine other psychiatrists at a dinner whether psychiatry only reduces symptoms, they would "probably not" agree.)
• The SSRI/Dopamine Paradox and Drug Purity: Psychotropics historically modulate monoamines (serotonin, dopamine, norepinephrine), and SSRIs are actually more effective for anxiety, OCD, and PTSD than depression. However, raising serotonin can downregulate dopamine and norepinephrine via receptor changes, causing cognitive dulling, affective blunting, a lack of "oomph," and worsened attention in ADHD patients. Escitalopram (Lexapro, typically dosed at 10 mg, 20 mg, or a halved 5 mg) is the purest SSRI, whereas sertraline (Zoloft) mildly blocks dopamine reuptake. SNRIs like venlafaxine, desvenlafaxine (Pristiq), and duloxetine (Cymbalta) balance serotonin and norepinephrine, reducing blunting. Compared to older tricyclics (which caused severe anticholinergic side effects and were lethal in overdose) and MAOIs (which carried fatal hypertensive "cheese reaction" risks with tyramine), SSRIs are remarkably benign.
• Dysthymia vs. Major Depression: Major depression features a larger amplitude and lower frequency of episodes. Dysthymia (which escitalopram was developed to treat) is a chronic, high-frequency, lower-amplitude depressive tendency sitting below baseline, marked by irritability, pessimism, sadness, and lack of forward planning.
• Bipolar Spectrum Disorders and Adaptive Hypomania: While unipolar depression features irritability, untreated bipolar disorder is defined by "volatility." Most bipolar patients present complaining of depression, unaware of their diagnosis. In Bipolar II, hypomania can be highly adaptive; roughly one-third of Abrams' career patients have been highly successful individuals using hypomanic drive to achieve remarkable things (though Abrams notes the molecular/ion channel mechanisms of hypomania remain "very abstruse"). Prescribing an antidepressant alone for bipolar depression can trigger mood cycling, insomnia, racing thoughts, or dangerous mixed states (simultaneous hopelessness and physical agitation). Mood stabilizers like lamotrigine (which alters sodium channels) and lithium (whose exact mechanism Abrams states "I don't believe" we know) provide a "floor" and "ceiling" as first-line monotherapies. Hormonal shifts like perimenopause can also unmask latent Bipolar II.
• Evolutionary Mismatches and the Distress Tolerance Window: While Abrams speculates hypothetically that depressive diurnal variation and hypersomnia may have been evolutionarily conserved to keep humans in caves during winter or to force a psychological reappraisal of one's world model, clinical depression is destructive and lethal. Modernity drives rising depression via existential and environmental anxieties, social media algorithms, digital isolation, declining romance/sex/fertility, and increased online pornography. Conversely, missionary physician Dr. Tom Catena reported to Attia that among 1 million people he cares for in the war-torn Nuba Mountains of Sudan, the prevalence of depression is "none" due to tight-knit families and common purpose. Furthermore, hunter-gatherers did not suffer from insomnia (even when sleeping in shorter windows than 8 hours) because their circadian rhythms were environmentally aligned. Biological stressors—like poor sleep or a 6/10 dental pain lingering for 2 weeks—narrow one's "distress tolerance window," while chronic pain elevates cortisol, damages the hippocampus, and lowers BDNF.
• System Modulators (Hormones) vs. Signal Amplifiers (Psychotropics): Following the Women's Health Initiative (WHI) 25 years ago, general medicine largely abandoned hormone replacement, eroding adaptive capacity in men and women (though Abrams hesitates to make generalizations about his own practice immediately post-WHI due to his relative ignorance at the time). While psychotropics act as "signal amplifiers," estradiol is a "system modulator" that binds to membrane receptors (alpha and beta) and genomic estrogen response elements (EREs) to upregulate tryptophan hydroxylase (serotonin synthesis), tyrosine hydroxylase (dopamine synthesis), and choline acetyltransferase (acetylcholine synthesis), while modulating GABA, NMDA, glutamate, and BDNF.
• Hormonal Oscillations in PMDD and Postpartum: Psychopathology is driven more by hormonal fluctuations than absolute levels (though Abrams hedges he is not sure how high the correlation is between PMDD and postpartum/menopausal depression). In PMDD, progesterone is flatlined during the 14-day follicular phase, rises in the luteal phase, and crashes when implantation fails; this drop in allopregnanolone (a neurosteroid derivative of progesterone via 5-alpha-reductase and 3-alpha-hydroxysteroid dehydrogenase) triggers severe symptoms. In childbirth, estradiol plummets from ~30,000 to ~30 and progesterone drops from several hundred to <1 within 24 to 48 hours. Severe postpartum depression/psychosis (<1% prevalence) unfolds within a week with paranoia and OCD-like intrusive thoughts, and can be treated acutely with zuranolone (an oral synthetic analog of allopregnanolone that replaced the IV infusion brexanolone).
• Testosterone Dynamics and the Clomiphene Mismatch: Testosterone modulates dopamine in the mesolimbic (reward) and mesocortical (executive function/working memory) pathways; its gradual decline in andropause causes dulling, loss of vitality, and subclinical ADHD-like symptoms. Men also rely on testosterone as a prodrug for estradiol via aromatization. Women depend almost entirely on testosterone for libido and actually produce 10 times more testosterone than estradiol (and 1/10th the testosterone of men)—a fact obscured because labs report testosterone in ng/dL and estradiol in pg/mL (or "picograms per deciliter" as spoken in the episode, a 1,000-fold unit factor). In men, unregulated oral clomiphene/enclomiphene raises peripheral testosterone numbers while preserving fertility (unlike Schedule IV exogenous testosterone, and similar to Schedule IV injectable hCG), but blocks central estrogen/testosterone receptors at the hypothalamus. Attia hypothesizes (noting he has "no data to suggest why") that this central blockade explains the empirical "symptom-laboratory mismatch" where men on clomiphene have great lab numbers but feel no symptom relief.
• The Thyroid Axis in Psychiatry: Hypothyroidism presents as depression, whereas hyperthyroidism presents as somatic anxiety (racing heart, agitation, insomnia, as seen in a thyroid storm case Attia recalls with a TSH of 0 and elevated Free T4 from a hot nodule). Because TSH only reflects pituitary perception, patients in the top half of the "normal" 0.8 to 5.0 TSH range (2.5 to 5.0) often have a foundational thyroid deficiency dismissed by clinicians. T4 converts to T3 via deiodinase enzymes, and T3 boosts mitochondrial biogenesis, energy, catecholamine receptor responsiveness, and serotonin receptor density. While atypical antipsychotics—brexpiprazole (Rexulti), aripiprazole (Abilify), and olanzapine (Zyprexa)—can augment treatment-resistant depression, they carry dose- and duration-dependent risks of potentially irreversible tardive dyskinesia and tardive dystonia, making T3 (Cytomel) a vital alternative.
• Cortisol as a Secondary Signal: Unlike thyroid, androgen, or insulin axes that suffer from deficiency and respond to pharmacologic replacement, modern HPA-axis dysfunction usually involves chronic cortisol excess/hyperarousal. Cortisol is not a primary disease target with a pill antidote, but rather a secondary signal of unaddressed life stressors (such as caregiving for an Alzheimer's parent or toxic work environments).
• Ketamine, Psychedelics, and Pharmacokinetic Resistance: Ketamine is an NMDA receptor antagonist that disinhibits glutamate release, activating the mTOR pathway to drive rapid neuroplasticity. Infused up to 3 or more times a week, it rapidly dissipates suicidal ideation as a "bridge" treatment, though relief often lasts only days (Abrams admits he is "not that expert in ketamine" regarding tachyphylaxis, and notes that the true cause of long-term remission in any individual is "unknowable"). Classic psychedelics bind to serotonin 2A receptors to open a neuroplastic window to adjust maladaptive priors, as described in Robin Carhart-Harris's REBUS ("Relaxed Beliefs Under Psychedelics") model (blocking 5-HT2A receptors can require 20x the psychedelic dose). While an $N=1$ case report claimed 5 grams (and later 3 grams) of psilocybin reversed a 10-year severe Alzheimer's diagnosis, both speakers heavily caveat that it lacked neuroimaging or metrics and likely represented PTSD regression with mild cognitive impairment. Finally, individual pharmacokinetics vary wildly: Attia requires 2 to 3x standard doses of substances (feeling nothing from 4 alcoholic drinks, 4 cups of coffee, or 5 grams of psilocybin, requiring >10 grams), and experienced both a transformative empathy-building psilocybin trip viewing himself at age 12 through his parent's eyes, as well as a traumatizing psilocybin vision of a dropping guillotine blade and a horrific therapeutic ketamine experience he described as "Guantanamo Bay for my soul and my psyche."

Quotes

• At 0:02:51 - "What I finally decided was the organizing principle was that psychiatry aims at reduction of symptoms, not restoration of the full human experience that makes life most worthwhile." - Dr. Linus Abrams explaining the foundational limitation of traditional psychiatric care and why he integrated endocrinology into his practice.
• At 0:09:50 - "All the information that one gets from a trial of a psychotropic medication is useful information. So it isn't categorical, this is a good drug for this or a bad drug." - Dr. Linus Abrams discussing how a patient's positive or negative response to a medication helps clarify their underlying neurobiology and diagnosis.
• At 0:12:51 - "Raising serotonin can decrease dopamine. So someone, let's say, with attention deficit disorder who has low dopamine as part of the problem of their attention issues, if they go on an SSRI, they could exacerbate it." - Dr. Linus Abrams detailing the neurotransmitter cross-talk that causes SSRIs to worsen executive function in ADHD patients.
• At 0:13:29 - "Taking an SSRI alone can often make people feel a little bit blunted, not fully vital to the extent that they're desiring." - Dr. Linus Abrams describing the affective blunting and loss of vitality caused by serotonergic downregulation of dopamine and norepinephrine.
• At 0:16:11 - "It's actually a class of drugs that is more effective for anxiety than it is for depression, not to say that it's not effective for a lot of depression." - Dr. Linus Abrams clarifying why the term "antidepressant" is a misnomer for SSRIs.
• At 0:19:27 - "So major depression is more, has a bigger amplitude, but typically a lower frequency. Dysthymia is a chronic tendency, if you were to draw a graph of it, where the mood would be below the baseline to a degree that takes a toll on the quality of life of the person who has it." - Dr. Linus Abrams contrasting the clinical trajectories of episodic major depressive disorder and chronic dysthymia.
• At 0:26:46 - "I would say maybe over the course of my career, maybe a third of my patient population have been incredibly successful people who've used their hypomanic drive to achieve remarkable things." - Dr. Linus Abrams highlighting how Bipolar II hypomania can be highly adaptive in high-achieving individuals.
• At 0:28:56 - "The wrong drug would be, I would say, any antidepressant instead of a mood stabilizer, like lamotrigine. Because lamotrigine, sorry to interrupt, lamotrigine can be very effective about treating depression." - Dr. Linus Abrams warning against using standard antidepressants as monotherapy in bipolar depression.
• At 0:37:09 - "I would say depression is bad. It takes a huge toll on people, it can be lethal. It definitely increases the risk factors for a lot of medical problems." - Dr. Linus Abrams qualifying his evolutionary speculations by emphasizing the severe clinical danger of major depression.
• At 0:48:23 - "If you want to be able to sleep really, really well in the modern world, you have to do things that might feel unnatural, meaning you have to disconnect from your phone, you have to auto-correct the light in your environment." - Dr. Peter Attia explaining why maintaining circadian alignment in modernity requires deliberate, anti-normative behaviors.
• At 0:53:03 - "The brain doesn't operate in isolation, and it's part of this larger system with bidirectional feedback." - Dr. Linus Abrams bridging the discussion from lifestyle factors and chronic pain to systemic endocrinology.
• At 0:58:21 - "Estradiol is a constitutive, pleiotropic, multi-system regulator of neurotransmitters and neural circuits." - Dr. Linus Abrams defining the overarching role of estrogen in brain health and neurochemistry.
• At 0:59:30 - "While psychotropics are signal amplifiers, estradiol, for example, is a system modulator. It creates the conditions within which neurotransmission occurs." - Dr. Linus Abrams providing the core framework for why hormone optimization is foundational to psychopharmacology.
• At 1:01:16 - "And that, for example, is how serotonin synthesis is upgraded through tryptophan hydroxylase. There are specific estrogen response elements that bind to the promoting factors for tryptophan hydroxylase, therefore increasing serotonin." - Dr. Linus Abrams explaining the genomic mechanism by which estradiol directly increases serotonin production.
• At 1:09:45 - "Women are almost entirely dependent on testosterone for libido." - Dr. Linus Abrams emphasizing the critical role of androgens in female sexual health and vitality.
• At 1:10:45 - "Testosterone is reported in nanograms per deciliter, estradiol is reported in picograms per deciliter, so you have to normalize those because they're off by a factor of a thousand, and when you do that, you realize that a woman's testosterone level is about 10 times higher than her estradiol level, although it's about one-tenth the level of a man." - Dr. Peter Attia explaining how standard laboratory units obscure the true abundance of testosterone in female physiology.
• At 1:16:21 - "Estradiol goes from 30,000 to, let's say, 30. Progesterone goes from several hundred to less than one within 24 to 48 hours. It's amazing that women do as well as they do." - Dr. Linus Abrams illustrating the massive, rapid endocrine crash that precipitates postpartum psychiatric conditions.
• At 1:28:11 - "So if the normal range is 0.8 to 5.0, people, let's say, in the range of 2.5 to 5 are often considered normal and dismissed, but that's often indicative of a real foundational deficiency in thyroid hormone." - Dr. Linus Abrams critiquing standard medical interpretation of TSH lab values in depressed patients.
• At 1:42:20 - "The cortisol is a signal, as far as I'm concerned. It's not really the primary problem. It's a secondary manifestation of a primary stress problem that isn't being managed adaptively." - Dr. Linus Abrams explaining why elevated cortisol must be addressed through practical life changes rather than targeted with a medication.
• At 1:56:46 - "It absolutely needs to be controlled and supervised. If taken randomly, it's playing Russian roulette, as far as I'm concerned." - Dr. Linus Abrams warning against the unsupervised, recreational use of ketamine due to dissociation, unpredictable mood shifts, and addiction risk.

Takeaways

• Screen depressed patients thoroughly for historical periods of high energy, decreased need for sleep, racing thoughts, or chaotic life phases (Bipolar II hypomania) before prescribing an antidepressant; if bipolar spectrum disorder is present, initiate a mood stabilizer like lamotrigine or lithium first to prevent mixed states or mood cycling.
• Consider SNRIs (such as venlafaxine, desvenlafaxine, or duloxetine) or sertraline instead of pure SSRIs when treating depression in patients with clinical or subclinical ADHD, or in patients experiencing SSRI-induced cognitive dulling and affective blunting, while reserving aggressive SSRI therapy for OCD and PTSD.
• Adopt "anti-normative" daily behaviors to protect sleep architecture and widen your distress tolerance window: deliberately disconnect from phones, control evening artificial light exposure, prioritize outdoor daylight, exercise regularly, and aggressively resolve sources of chronic physical pain.
• Evaluate foundational sex hormones (estradiol, progesterone, and testosterone) in men and women presenting with midlife onset of depression, anxiety, brain fog, or loss of vitality, rather than immediately defaulting to psychotropic polypharmacy.
• Avoid giving aromatase inhibitors (such as Arimidex) to men on testosterone therapy unless strictly necessary, as men require the aromatization of testosterone into estradiol for optimal brain and systemic function.
• Normalize laboratory units when evaluating female hormone panels (accounting for the 1,000-fold difference between ng/dL and pg/mL) and consider testosterone replacement in women suffering from low libido and diminished vitality.
• Prefer injectable exogenous testosterone cypionate over clomiphene (Clomid) for symptomatic hypogonadal men who do not need to preserve fertility, as clomiphene's blockade of central brain receptors frequently leaves men symptomatic despite normalized blood levels.
• Treat uncomplicated, first-time outpatient postpartum depression with an evidence-based antidepressant course of 8 to 12 months before initiating a slow taper, and consider oral zuranolone for acute, severe postpartum depression.
• Do not rely solely on a "normal" TSH to rule out thyroid dysfunction in depressed patients; measure Free T4 and Free T3, and investigate foundational thyroid deficiency when TSH sits in the upper half of the normal range (2.5 to 5.0), while referring overt hypothyroidism (e.g., TSH of 7 or 10) to an endocrinologist.
• In treatment-resistant depression, consider augmenting with FDA-approved immediate-release T3 (Cytomel/liothyronine) rather than compounded time-release formulas—starting at 2.5 to 5 mcg twice daily (morning and 6 to 8 hours later) and titrating up to 25 mcg twice daily while monitoring blood pressure and pulse—before resorting to atypical antipsychotics that carry tardive dyskinesia risks.
• Address chronic HPA-axis hyperarousal and elevated cortisol by making concrete structural changes to primary life stressors (such as securing caregiving support, changing toxic work environments, or reducing overwork) rather than searching for a pharmacological cortisol blocker.
• Restrict ketamine therapy to supervised clinical settings as a short-term bridge to rapidly resolve acute suicidal ideation, and approach classic psychedelics with strict attention to set, setting, drug interactions (such as 5-HT2A blockers), and individual pharmacokinetic dose-response curves.